1. KD. Tripathi. Drugs used in mental illness: Antipsychotic and Antimanic drugs. Essentials of medical pharmacology. Seventh edition. 2013.Page – 443.
2. Sanofi. Study of the Efficacy and Safety After Long-Term Treatment with Amisulpride in Schizophrenic Patients. NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on April 2008] [Accessed 3rd November 2020] https://clinicaltrials.gov/ct2/show/NCT00331981
3. Katja Komossa, Christine Rummel-Kluge, Heike Hunger, Franziska Schmid, Sandra Schwarz, Joaquim I Silveira da Mota Neto, Werner Kissling, and Stefan Leucht. Amisulpride versus other atypical antipsychotics for schizophrenia. NCBI; PMC National Library of Medicine, National Institute of Health. January 2010. [Accessed 3rd November 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164462/
4. Peng Men, Zhanmiao Yi, Chaoyun Li, Shuli Qu, Tengbin Xiong, Xin Yu & Suodi Zhai. Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis. BMC Psychiatry. September 2018. [Accessed 3rd November 2020] https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-018-1867-8
5. Milpharm Limited, APL Swift Services (Malta) Ltd. Electronic Medicines Compendium (EMC); [Revised on April 2020] [Accessed 3rd November 2020] https://www.medicines.org.uk/emc/files/pil.548.pdf
6. Delpharm Dijon. Electronic Medicines Compendium (EMC); [Revised on October 2019] [Accessed 3rd November 2020] https://www.medicines.org.uk/emc/files/pil.3964.pdf